Daniel Joyce, MD, of Vanderbilt University Medical Center, and Sarah Psutka, MD, MSc, of Fred Hutchinson Cancer Center, meet at the AUA 2024 Annual Meeting to contextualize updates in kidney cancer research and how the treatment paradigm is changing as a result of KEYNOTE-564. Together, they consider patient selection and counseling for adjuvant therapy, biomarkers and imaging before treatment, and a need to shift away from clinical outcomes in favor of patient outcomes. ...
Renal Cell Carcinoma Diagnostics
Advertisement
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
A new study by an international research team has identified new susceptibility regions associated with RCC development risk.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
Advertisement
Video Insights
Conferene Coverage
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Advertisement
Section Editor
Daniel Joyce, MDDepartment of Urology | Vanderbilt University Medical Center
Advertisement
Get the latest RCC research straight to your inbox.
